(3-氟-4-甲氧基苯基)肼氯化物 | 220527-84-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3-氟-4-甲氧基苯基)肼氯化物
• 英文名称: 3-fluoro-4-methoxyphenylhydrazine hydrochloride
• 英文别名: (3-Fluoro-4-methoxy-phenyl) hydrazine hydrochloride；(3-fluoro-4-methoxyphenyl)hydrazine;hydrochloride
• CAS: 220527-84-4
• 化学式: C₇H₉FN₂O*ClH
• 分子量: 192.621
• InChiKey: CZBBSMVGFZLCEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.59
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  48.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3-氟-4-甲氧基苯基)肼氯化物 在 Raney nickel 乙醇 、 水 作用下， 以 异丁醇 为溶剂， 反应 5.0h， 生成 6-fluoro-5-methoxy-2-methyl-1H-indole
  参考文献：
  名称：

  [EN] FAAH INHIBITORS
  [FR] INHIBITEURS DE FAAH

  摘要：

  本公开涉及作为脂肪酰胺水解酶（FAAH）抑制剂有用的化合物。该公开还提供包括本公开化合物的药学上可接受的组合物，以及使用这些组合物在治疗或预防各种疾病中的方法。发明的化合物在表1中描述。

  公开号：

  WO2012088469A1
• 作为产物：
  描述：

  2-氟苯甲醚 在 10percent Pd/C 盐酸 、 硫酸 、 氢气 、 硝酸 、 sodium nitrite 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、310.27 kPa 条件下， 反应 19.42h， 生成 (3-氟-4-甲氧基苯基)肼氯化物
  参考文献：
  名称：

  Effect of Ring Fluorination on the Pharmacology of Hallucinogenic Tryptamines

  摘要：

  A series of fluorinated analogues of the hallucinogenic tryptamines N,N-diethyltryptamine (DET), 4-hydroxy-N,N-dimethyltryptamine (4-OH-DMT, psilocin), and 5-methoxy-DMT was synthesized to investigate possible explanations for the inactivity of 6-fluoro-DET as a hallucinogen and to determine the effects of fluorination on the molecular recognition and activation of these compounds at serotonin receptor subtypes. The target compounds were evaluated using in vivo behavioral assays for hallucinogen-like and 6-HT1A agonist activity and in vitro radioligand competition assays for their affinity at 5-HT2A, 5-HT2C, and 5-HT1A receptor sites. Functional activity at the 5-HT2A receptor was determined for all compounds. In addition, for some compounds functional activity was determined at the 5-HT1A receptor. Hallucinogen-like activity, evaluated in the two-lever drug discrimination paradigm using LSD-trained rats, was attenuated or abolished for all of the fluorinated analogues. One of the tryptamines, 4-fluoro-5-methoxy-DMT (6), displayed high 5-HT1A agonist activity, with potency greater than that of the 5-HT1A agonist 8-OH-DPAT. The ED50 Of 6 in the two-lever drug discrimination paradigm using rats trained to discriminate the 5-HT1A agonist LY293284 was 0.17 mu mol/kg, and the K-i at [H-3] 8-OH-DPAT-labeled 5-HT1A receptors was 0.23 nM. The results indicate that fluorination of hallucinogenic tryptamines generally has little effect on 5-HT2A/2C receptor affinity or intrinsic activity. Affinity at the 5-HT1A receptor was reduced, however, in all but one example, and all of the compounds tested were full agonists but with reduced functional potency at this serotonin receptor subtype. The one notable exception was 4-fluoro-5-methoxy-DMT (6), which had markedly enhanced 5-HT1A receptor affinity and functional potency. Although it is generally considered that hallucinogenic activity results from 5-HT2A receptor activation, the present results suggest a possible role for involvement of the 5-HT1A receptor with tryptamines.

  DOI：

  10.1021/jm000339w

文献信息

• Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts
  申请人：SHANGHAI HYBRID-CHEM TECHNOLOGIES

  公开号：US20190152896A1

  公开（公告）日：2019-05-23

  The present invention provided a continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts. Diazotization, reduction, acidic hydrolysis and salifying with acids are innovatively integrated together. Using acidic liquids of aniline or substituted aniline, diazotization reagents, reductants and acids as raw materials, phenylhydrazine derivative salts is obtained through the synthesis process, which is a three-step continuous tandem reaction including diazotization, reduction, acidic hydrolysis and salifying. The described synthesis process is a kind of integrated solutions, which is carried out in an integrated reactor. The feed inlets of the integrated reactor are continuously filled with raw materials. In the integrated reactor, diazotization, reduction, acidic hydrolysis and salifying are carried out continuously and orderly, and phenylhydrazine salts or substituted phenylhydrazine salts is obtained in the outlet of the integrated reactor without interruption. The total reaction time is no more than 20 min.

  本发明提供了一种连续流程，用于合成苯肼盐和取代苯肼盐。重氮化、还原、酸性水解和酸化与酸类创新地集成在一起。使用苯胺或取代苯胺的酸性液体、重氮化试剂、还原剂和酸类作为原料，通过合成过程获得苯肼衍生物盐，这是一个包括重氮化、还原、酸性水解和酸化的三步连续串联反应。所述的合成过程是一种集成解决方案，是在一个集成反应器中进行的。集成反应器的进料口连续填充原料。在集成反应器中，重氮化、还原、酸性水解和酸化被连续有序地进行，苯肼盐或取代苯肼盐在集成反应器的出口处获得，没有中断。总反应时间不超过20分钟。
• Anhydrous Hydrogen Iodide-Mediated Reductive Indolization of In Situ-Generated Cyclopropyl Hydrazones
  作者：Motohiro Yasui、Hiroki Fujioka、Norihiko Takeda、Masafumi Ueda

  DOI：10.1021/acs.orglett.1c03607

  日期：2022.1.14

  Fischer-type indolization of N-aryl-C-cyclopropyl hydrazones generated in situ followed by chemoselective reduction using tert-butyl iodide as an anhydrous HI generator was developed. This protocol provides indoles bearing carboxylic acid derivative units. A series of control experiments indicated the HI-mediated formation and reduction of spirocyclopropyl indolenines. Anhydrous HI functions as a Brønsted

  开发了原位产生的N-芳基-C-环丙基腙的 Fischer 型吲哚化，然后使用叔丁基碘作为无水 HI 发生器进行化学选择性还原。该协议提供了带有羧酸衍生物单元的吲哚。一系列对照实验表明 HI 介导的螺环丙基二氢吲哚的形成和还原。无水 HI 可作为布朗斯台德酸和还原剂，促进不稳定反应中间体和碘化混合物在平衡状态下的成功转化。
• [EN] CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR<br/>[FR] INHIBITEUR DE CETP SUBSTITUÉ PAR DES AMINES CYCLIQUES À BASE D'OXAZOLIDINONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012058187A1

  公开（公告）日：2012-05-03

  CCompounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substitiuted phenyl group or indanyl group.Formula (I).

  具有公式I结构的化合物，包括这些化合物的药用盐，是CETP抑制剂，可用于提高HDL胆固醇，降低LDL胆固醇，并用于治疗或预防动脉粥样硬化。在公式I的化合物中，A3是一个取代苯基或茚基。公式（I）。
• PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Arrien Pharmaceuticals LLC

  公开号：US20200131154A1

  公开（公告）日：2020-04-30

  Compounds having activity as chemotherapeutic agents are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R 1a , R 1b , R 1c , R 1d , L, and are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods for treating cancer (e.g., hematological cancers) are also provided.

  提供具有化疗药物活性的化合物。这些化合物具有以下结构（I）：或其药用可接受盐、立体异构体、同位素形式或前药，其中R1a、R1b、R1c、R1d、L和在此定义。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及治疗癌症（例如血液系统癌症）的方法。
• [EN] PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ DÉRIVÉ DE PYRAZOLE ET SON UTILISATION
  申请人：HANMI PHARM IND CO LTD

  公开号：WO2019054766A1

  公开（公告）日：2019-03-21

  Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.

  提供的是一种由化学式1表示的化合物，具有对赖氨酸特异性去甲基化酶-1（LSD1）具有抑制活性的光学异构体、溶剂化合物、互变异构体或其药用可接受盐，可有效预防或治疗由LSD1异常活化引起的疾病。